Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
2.340
+0.120 (5.41%)
Dec 5, 2025, 4:00 PM EST - Market closed
CELZ Revenue
Creative Medical Technology Holdings had revenue of $6.00K in the twelve months ending September 30, 2025, down -45.45% year-over-year. In the year 2024, Creative Medical Technology Holdings had annual revenue of $11.00K with 22.22% growth.
Revenue (ttm)
$6.00K
Revenue Growth
-45.45%
P/S Ratio
1,441.70
Revenue / Employee
$1,500
Employees
4
Market Cap
8.65M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CELZ News
- 4 days ago - Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 - GlobeNewsWire
- 5 weeks ago - Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits - GlobeNewsWire
- 5 weeks ago - Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds - GlobeNewsWire
- 5 weeks ago - Creative Medical Technology Holdings Issues Letter to Shareholders - GlobeNewsWire
- 2 months ago - Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling - GlobeNewsWire
- 9 months ago - Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain - GlobeNewsWire